DOI QR코드

DOI QR Code

Adverse Events in Total Artificial Heart for End-Stage Heart Failure: Insight From the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE)

  • Min Choon Tan (Division of Cardiovascular Medicine, Mayo Clinic Arizona) ;
  • Yong Hao Yeo (Department of Internal Medicine, Beaumont Health) ;
  • Jia Wei Tham (Perdana University-Royal College of Surgeons in Ireland) ;
  • Jian Liang Tan (Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania) ;
  • Hee Kong Fong (Division of Cardiovascular Medicine, UC Davis Medical Center) ;
  • Bryan E-Xin Tan (Department of Internal Medicine, Rochester General Hospital) ;
  • Kwan S Lee (Division of Cardiovascular Medicine, Mayo Clinic Arizona) ;
  • Justin Z Lee (Division of Cardiovascular Medicine, Cleveland Clinic)
  • Received : 2023.03.20
  • Accepted : 2023.09.09
  • Published : 2024.04.30

Abstract

Background and Objectives: Real-world clinical data, outside of clinical trials and expert centers, on adverse events related to the use of SyncCardia total artificial heart (TAH) remain limited. We aim to analyze adverse events related to the use of SynCardia TAH reported to the Food and Drug Administration (FDA)'s Manufacturers and User Defined Experience (MAUDE) database. Methods: We reviewed the FDA's MAUDE database for any adverse events involving the use of SynCardia TAH from 1/01/2012 to 9/30/2020. All the events were independently reviewed by three physicians. Results: A total of 1,512 adverse events were identified in 453 "injury and death" reports in the MAUDE database. The most common adverse events reported were infection (20.2%) and device malfunction (20.1%). These were followed by bleeding events (16.5%), respiratory failure (10.1%), cerebrovascular accident (CVA)/other neurological dysfunction (8.7%), renal dysfunction (7.5%), hepatic dysfunction (2.2%), thromboembolic events (1.8%), pericardial effusion (1.8%), and hemolysis (1%). Death was reported in 49.4% of all the reported cases (n=224/453). The most common cause of death was multiorgan failure (n=73, 32.6%), followed by CVA/other non-specific neurological dysfunction (n=44, 19.7%), sepsis (n=24, 10.7%), withdrawal of support (n=20, 8.9%), device malfunction (n=11, 4.9%), bleeding (n=7, 3.1%), respiratory failure (n=7, 3.1%), gastrointestinal disorder (n=6, 2.7%), and cardiomyopathy (n=3, 1.3%). Conclusions: Infection was the most common adverse event following the implantation of TAH. Most of the deaths reported were due to multiorgan failure. Early recognition and management of any possible adverse events after the TAH implantation are essential to improve the procedural outcome and patient survival.

Keywords

References

  1. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation 2022;145:e153-639.
  2. Metra M, Ponikowski P, Dickstein K, et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2007;9:684-94. https://doi.org/10.1016/j.ejheart.2007.04.003
  3. Colvin M, Smith JM, Hadley N, et al. OPTN/SRTR 2016 annual data report: heart. Am J Transplant 2018;18 Suppl 1:291-362. https://doi.org/10.1111/ajt.14561
  4. Bakhtiyar SS, Godfrey EL, Ahmed S, et al. Survival on the heart transplant waiting list. JAMA Cardiol 2020;5:1227-35. https://doi.org/10.1001/jamacardio.2020.2795
  5. Coyan GN, Huckaby LV, Diaz-Castrillon CE, Miguelino AM, Kilic A. Trends and outcomes following total artificial heart as bridge to transplant from the UNOS database. J Card Surg 2022;37:1215-21. https://doi.org/10.1111/jocs.16329
  6. Copeland JG, Copeland H, Gustafson M, et al. Experience with more than 100 total artificial heart implants. J Thorac Cardiovasc Surg 2012;143:727-34. https://doi.org/10.1016/j.jtcvs.2011.12.002
  7. Razumov A, Deutsch M, Lauenroth V, et al. Biventricular support with SynCardia total artificial heart: long-term single-center experience. J Heart Lung Transplant 2020;39 Suppl:S336-7. https://doi.org/10.1016/j.healun.2020.01.369
  8. Roussel JC, Senage T, Baron O, et al. CardioWest (Jarvik) total artificial heart: a single-center experience with 42 patients. Ann Thorac Surg 2009;87:124-9. https://doi.org/10.1016/j.athoracsur.2008.09.048
  9. Chambers HE, Pelish P, Qiu F, Florescu DF. Perioperative prophylaxis for total artificial heart transplantation. Transplant Proc 2017;49:2169-75. https://doi.org/10.1016/j.transproceed.2017.09.020
  10. Seidelman JL, Mantyh CR, Anderson DJ. Surgical site infection prevention: a review. JAMA 2023;329:244-52. https://doi.org/10.1001/jama.2022.24075
  11. Zukowska A, Zukowski M. Surgical site infection in cardiac surgery. J Clin Med 2022;11:6991.
  12. Arabia FA, Cantor RS, Koehl DA, et al. Interagency registry for mechanically assisted circulatory support report on the total artificial heart. J Heart Lung Transplant 2018;37:1304-12. https://doi.org/10.1016/j.healun.2018.04.004
  13. Carrier M, Moriguchi J, Shah KB, et al. Outcomes after heart transplantation and total artificial heart implantation: a multicenter study. J Heart Lung Transplant 2021;40:220-8. https://doi.org/10.1016/j.healun.2020.11.012
  14. Demondion P, Fournel L, Niculescu M, Pavie A, Leprince P. The challenge of home discharge with a total artificial heart: the La Pitie Salpetriere experience. Eur J Cardiothorac Surg 2013;44:843-8. https://doi.org/10.1093/ejcts/ezt146
  15. Torregrossa G, Morshuis M, Varghese R, et al. Results with SynCardia total artificial heart beyond 1 year. ASAIO J 2014;60:626-34. https://doi.org/10.1097/MAT.0000000000000132
  16. El-Banayosy A, Arusoglu L, Morshuis M, et al. CardioWest total artificial heart: Bad Oeynhausen experience. Ann Thorac Surg 2005;80:548-52. https://doi.org/10.1016/j.athoracsur.2005.02.084
  17. Nguyen A, Pellerin M, Perrault LP, et al. Experience with the SynCardia total artificial heart in a Canadian centre. Can J Surg 2017;60:375-9. https://doi.org/10.1503/cjs.003617
  18. Copeland J, Copeland H, Nolan P, Gustafson M, Slepian M, Smith R. Results with an anticoagulation protocol in 99 SynCardia total artificial heart recipients. ASAIO J 2013;59:216-20. https://doi.org/10.1097/MAT.0b013e318288a390
  19. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009;28:535-41. https://doi.org/10.1016/j.healun.2009.02.015
  20. Shah KB, Thanavaro KL, Tang DG, et al. Impact of INTERMACS profile on clinical outcomes for patients supported with the total artificial heart. J Card Fail 2016;22:913-20. https://doi.org/10.1016/j.cardfail.2016.04.016
  21. Johnson KE, Prieto M, Joyce LD, Pritzker M, Emery RW. Summary of the clinical use of the Symbion total artificial heart: a registry report. J Heart Lung Transplant 1992;11:103-16.
  22. Joyce LD, Joyce DL. Total artificial heart: neurological complications. Ann Cardiothorac Surg 2020;9:121-3. https://doi.org/10.21037/acs.2020.02.14
  23. Ensor CR, Cahoon WD, Crouch MA, et al. Antithrombotic therapy for the CardioWest temporary total artificial heart. Tex Heart Inst J 2010;37:149-58.
  24. Ramirez A, Riley JB, Joyce LD. Multi-targeted antithrombotic therapy for total artificial heart device patients. J Extra Corpor Technol 2016;48:27-34. https://doi.org/10.1051/ject/201648027
  25. Volod O, Lam LD, Arabia FA. Antithrombotic therapy for patients with total artificial hearts. Ann Cardiothorac Surg 2020;9:110-2. https://doi.org/10.21037/acs.2019.12.01
  26. Hsich EM. Matching the market for heart transplantation. Circ Heart Fail 2016;9:e002679.
  27. Ramu B, Cogswell RJ, Reding MT, John R, Martin CM. Plasma exchange to remove heparin-induced thrombocytopenia antibodies and the use of heparin during cardiopulmonary bypass in critically ill cardiac patients. J Heart Lung Transplant 2018;37:1038-40. https://doi.org/10.1016/j.healun.2018.04.016
  28. Senage T, David CH, Nanjaiah P, Roussel JC. Total artificial heart: patient selection and risk factors. Ann Cardiothorac Surg 2020;9:118-20. https://doi.org/10.21037/acs.2020.02.10